New neuromuscular blockers;Nuevos bloqueadores neuromusculares

Medicina Intensiva

Volumn 25, Issue 9, 2001, Pages 340-343

  Chamorro, C ^a   Romera, M A ^a   Pardo, C ^a   Silva, J A ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Atracurium; Cisatracurium; Critical patient; Monitoring; Neuromuscular blocking agents; Rocuronium; Vecuronium

Indexed keywords

ATRACURIUM; CISATRACURIUM; HISTAMINE; NEUROMUSCULAR BLOCKING AGENT; ROCURONIUM; VECURONIUM;

CRITICAL ILLNESS; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; DRUG MARKETING; DRUG SAFETY; HISTAMINE RELEASE; HUMAN; NEUROMUSCULAR DISEASE; PATIENT MONITORING; REVIEW;

EID: 0035706961     PISSN: 02105691     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-5691(01)79719-7     Document Type: Review

References (36)

1. Uso racional de los bloqueadores neuromusculares en la unidad de cuidados intensivos
2. Pharmacodynamics of the IR cis- 1'R cis isomer of atracurium (51W89) in health and chronic renal failure
3. Intubating conditions following 1R CIS, 1'R CIS atracurium (51W89). A comparison with atracurium
4. The pharmacodynamics and pharmacokinetics of cisatracurium in patients with renal or hepatic failure
5. Cardiovascular and neurological effects of laudonosine. Studies in mice and rats and in conscious and anaesthetized dogs
6. Clinical experience and plasma laudanosine concentrations during the infusion of atracurium in the intensive therapy unit
7. Dispositions of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU
8. Atracurium and status epilepticus?
9. Ensayos clínicos sobre bloqueadores neuromusculares en pacientes críticos
10. The infusion requirements and recovery characteristics of cisatracurium or atracurium in intensive care patients
11. Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit
12. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients
13. The pharmacokinetics and the pharmacokinetic-dynamic relationship of rocuronium bromide
14. Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrosis
15. The use of rocuronium (Org 9426) in patients with chronic renal failure
16. Persistent paralysis in critically ill patients after long-term administration of vecuronium
17. Uso de rocuronio en la secuencia rápida de inducción-intubación de los pacientes críticos
18. Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients
19. Continuous infusion or rocuronium in a paediatric intensive care unit
20. Long-term use of rocuronium in ICU patients with or without multi organ failure
21. Rocuronium: High risk for anaphylaxis?
22. Intensive care sedation: A review of current British practice
23. Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure. A national survey
24. Lack of effect of induction of hypothermia after acute brain injury
25. Sedoanalgesia-relajación en la unidad de cuidados intensivos. Situación en España
26. Use of muscle relaxants in intensive care units
27. Neuromuscular blockade. Should patients be relaxed in the ICU?
28. Neuromuscular blockade in the intensive care unit. More than we bargained for
29. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: A review of the literature
30. Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit
31. The impact of implementation of neuromuscular blockade monitoring standars in a surgical intensive care unit
32. Double-blind, randomized, multicenter study of doxacurium vs. pancuronium in intensive care unit patients who require neuromuscular-blocking agents
33. Long-term administration of pancuronium and pipecuronium in the intensive care unit
34. Long term propofol infusion and cardiac failure in adult head-injured patients
35. Nivel mínimo de bloqueo neuromuscular en pacientes críticos durante el uso de bloqueadores neuromusculares
36. Monitoring neuromuscular function in the intensive care unit